The role of EVI1 gene quantification in AML patients with 11q23/MLL rearrangement after allogeneic hematopoietic stem cell transplantation

It remains unclear about the role of the EVI1 gene in AML patients with 11q23/MLL rearrangement (MLL-r AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). We analyzed the clinical value of EVI1 gene quantification in 96 MLL-r AML patients. High EVI1 expression was found in 73% (70/96) of MLL-r AML patients, and EVI1-high MLL-r AML patients were characterized by high WBC counts (P = 0.046) and low platelet counts (P < 0.001) and commonly hadt(6;11) (P = 0.032). In addition, a significant difference was observed in the SETD2 gene mutation between the EVI1 high and low groups (0% vs. 50%,P < 0.001). EVI1-high MLL-r AML patients had worse 2-year OS (49.8% vs. 79.7%,P = 0.01) and 2-year PFS (40.2% vs. 68.1%,P = 0.014) than EVI1-low patients. In 57 MLL-r AML patients undergoing allo-HSCT, poorer 2-year PFS (48.6% vs. 72.4%,P = 0.039) and higher CIR (33.2% vs. 11.1%,P = 0.035) were observed in the EVI1-high patients. Multivariate analysis revealed that pre-EVI1(+)was the sole independent factor of high CIR (P = 0.035, HR = 4.97, 95% CI: 1.12-22.04). EVI1(+)at 100 days post allo-HSCT was associated with a significantly higher 2-year CIR (P = 0.017). The quantification of the EVI1 gene could be used as an additional marker for early predicting relapse in allo-HSCT MLL-r AML patients.

Automated summary

The quantification of the EVI1 gene in MLL-r AML patients undergoing allo-HSCT showed that high EVI1 expression was associated with poorer overall survival, disease-free survival, and higher relapse rates. EVI1 could serve as an important marker for early prediction of relapse in these patients.